Regeneron answers rivals with data for new version of top-selling eye drug
BioPharma
Source: biopharmadive.com
📰 Roche Lucentis News
Roche Lucentis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Roche Lucentis. Real-time updates on events, politics, business and more.
Opthea lines up $260M to show how eye drug compares to blockbuster AMD meds
The wet form of age-related macular degeneration (AMD) is currently treated with eye drugs that are blockbuster sellers. Opthea Limited is developing a wet AMD drug that goes after different targets and the biotech struck a pair of financing deals that provide it with the cash for pivotal tests that could show how well its approach works.
Roche Lucentis Novartis Beovu Megan Baldwin European Union Australia Based Opthea Launch Therapeutics
Source: medcitynews.com
Global Pharmaceutical Contract Manufacturing Market is
 Visiongain has launched a new report on the Global Pharmaceutical Contract Manufacturing Market Forecast 2022-2032: - Market Segment by Services...
Source: globenewswire.com
Implications of Expanded Biosimilar Use in the United States' Dermatology, Gastroenterology, Rheumatology, Ophthalmology, Nephrology, and Neurology Markets Highlighted in New Spherix Study
/PRNewswire/ -- Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products),...
United States Boehringer Ingelheim Cyltezo Teva Celltrion Truxima Abbvie Humira Janssen Procrit Merck Hadlima
Source: prnewswire.com
Implications of Expanded Biosimilar Use in the United States' Dermatology, Gastroenterology, Rheumatology, Ophthalmology, Nephrology, and Neurology Markets Highlighted in New Spherix Study
/PRNewswire/ -- Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products),...
United States Boehringer Ingelheim Cyltezo Teva Celltrion Truxima Abbvie Humira Janssen Procrit Merck Hadlima
Source: prnewswire.com
Unity, on the rebound after catastrophe, shows promising results in early eye disease trial
Unity Biotechnology CEO Anirvan Ghosh, Ph.D. (Unity) Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular eye disease. The anti-aging biotech said Tuesday its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Unity ...
Source: fiercebiotech.com
Global Diabetic Retinopathy Drug Forecast and Market Analysis to 2029 - Press Release
Global Diabetic Retinopathy Drug Forecast and Market Analysis to 2029 ResearchAndMarkets.coms offering. Currently, only severe forms of diabetic retinopathy such as PDR and severe NPDR are managed with pharmacotherapy. The standard of care for DME and RVO are anti-angiogenic agents which inhibit vascular endothelial growth factor (VEGF). The most frequently used anti-VEGF drugs are Roche/Genentechs humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regenerons fu...
United Kingdom Roche Genentech Roche Lucentis Bayer Regeneron Eylea Allergan Ozurdex Alimera Iluvien
Source: digitaljournal.com